TY - BOOK AU - Dicker,Adam P. AU - Kelly,WmKevin AU - Zaorsky,Nicholas G. AU - Trabulsi,Edouard J. TI - Prostate cancer: a multidisciplinary approach to diagnosis and management T2 - Current multidisciplinary oncology series SN - 9781617051067 AV - RC280.P7 U1 - 616.99/463 23 PY - 2015///] CY - New York PB - DemosMedical KW - Prostate KW - Cancer KW - Diagnosis KW - Treatment KW - Health care teams KW - Prognosis KW - Prostate-specific antigen KW - Prostatic Neoplasms KW - diagnosis KW - Early Detection of Cancer KW - Patient Care Team KW - Prostate-Specific Antigen KW - therapy KW - Traitement KW - Soins médicaux KW - Travail en équipe KW - Pronostics (Pathologie) KW - Antigène prostatique spécifique KW - HEALTH & FITNESS KW - Diseases KW - bisacsh KW - MEDICAL KW - Oncology KW - fast KW - Electronic books N1 - Includes bibliographical references and index; Part I: Epidemiology, screening, and diagnosis -- Introduction: the multidisciplinary approach to prostate cancer -- Epidemiology of prostate cancer -- Diet and prostate cancer -- Epidemiology: obesity as a risk factor -- Screening and diagnosis: the pros of PSA screening -- The argument against prostate cancer screening -- How do we improve PSA accuracy? -- Screening and diagnosis: an update on the ISUP-modified Gleason score and its controversies -- Evaluation of distant disease: the utility of nuclear imaging -- Current approaches to prostate cancer staging and risk stratification: in the midst of a paradigm shift -- Novel molecular and genotype profiling in prostate cancer: the future of screening, diagnosis, and staging -- Genomics and risk assessment -- Future direction: novel urine and serum markers -- Morphometric and systems pathology: the future of screening, diagnosis, and staging -- PET: the future of screening, diagnosis, and staging for prostate cancer -- DCE MRI and MR spectroscopy: the future of screening, diagnosis, and staging -- Future direction: contrast ultrasound -- Counseling patients with clinically localized, high-risk prostate cancer -- Part II: Treatment for low-risk, localized disease -- Active surveillance for prostate cancer: an overview -- Treatment of low-risk, localized prostate cancer: a holistic approach with diet -- Traditional radical prostatectomy -- Laparoscopic radical prostatectomy: techniques and complications -- Robotic radical prostatectomy: the Thomas Jefferson University experience -- Surgical training, digital capture, virtual reality, and the future of radical prostatectomy -- External beam radiation therapy: conventional fractionation -- Hypofractionated radiation therapy for localized prostate cancer -- Stereotactic body radiation therapy for localized prostate cancer -- Treatment of low-risk, localized prostate cancer: use of proton therapy -- Treatment of low-risk, localized prostate cancer: brachytherapy -- Treatment of low-risk, localized prostate cancer: general principles of ablative and focal therapies -- Hyperthermia for prostate cancer -- Ablative techniques: vascular targeted photodynamic therapy -- Laser ablative techniques for prostate cancer -- Irreversible electroporation (IRE) prostate ablation -- Quality of life with surgery -- Quality of life with androgen deprivation therapy -- Quality of life with external beam radiation therapy -- Quality of life with brachytherapy for low-risk localized prostate cancer -- Role for comparative effectiveness research in treatment decision making -- Defining treatment failure for localized prostate cancer: PSA and beyond -- Prognosis after biochemical failure and surrogate endpoints for prostate cancer-specific mortality -- Part III: Treatment for high-risk, localized, and locally advanced disease -- treatment of high-risk prostate cancer: the role of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy -- Part IV: Treatment of disseminated disease -- Salvage therapy for rising PSA -- Metastatic hormone sensitive prostate cancer -- Metastatic castrate-resistant prostate cancer: mechanisms of hormone escape -- Metastatic castrate-resistant prostate cancer: role of chemotherapy and multifaceted treatment paradigms -- Metastatic castrate-resistant prostate cancer: role of androgen signaling inhibitors -- Radiation and the immune system -- Immunotherapy: agents targeting prostate cancer -- Treatment of bony metastases: inhibitors of bone resorption -- Treatment of bone metastases: radiopharmaceuticals -- Prognostication of metastatic castration-resistant prostate cancer N2 - "With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice"--Publisher's description UR - https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=933020 ER -